These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

114 related articles for article (PubMed ID: 15261132)

  • 1. The future of pharmacologic stress: selective A2A adenosine receptor agonists.
    Cerqueira MD
    Am J Cardiol; 2004 Jul; 94(2A):33D-40D; discussion 40D-42D. PubMed ID: 15261132
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Advances in pharmacologic stress agents: focus on regadenoson.
    Johnson SG; Peters S
    J Nucl Med Technol; 2010 Sep; 38(3):163-71. PubMed ID: 20724531
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Regadenoson.
    Garnock-Jones KP; Curran MP
    Am J Cardiovasc Drugs; 2010; 10(1):65-71. PubMed ID: 20063904
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Regadenoson in the detection of coronary artery disease.
    Buhr C; Gössl M; Erbel R; Eggebrecht H
    Vasc Health Risk Manag; 2008; 4(2):337-40. PubMed ID: 18561509
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Regadenoson (CV Therapeutics/Astellas).
    Eggbrecht H; Gössl M
    Curr Opin Investig Drugs; 2006 Mar; 7(3):264-71. PubMed ID: 16555687
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Novel short-acting A2A adenosine receptor agonists for coronary vasodilation: inverse relationship between affinity and duration of action of A2A agonists.
    Gao Z; Li Z; Baker SP; Lasley RD; Meyer S; Elzein E; Palle V; Zablocki JA; Blackburn B; Belardinelli L
    J Pharmacol Exp Ther; 2001 Jul; 298(1):209-18. PubMed ID: 11408544
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Regadenoson: review of its established role in myocardial perfusion imaging and emerging applications.
    Palani G; Ananthasubramaniam K
    Cardiol Rev; 2013; 21(1):42-8. PubMed ID: 22643345
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparative profile of vasodilation by CVT-3146, a novel A2A receptor agonist, and adenosine in conscious dogs.
    Zhao G; Linke A; Xu X; Ochoa M; Belloni F; Belardinelli L; Hintze TH
    J Pharmacol Exp Ther; 2003 Oct; 307(1):182-9. PubMed ID: 12954805
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Recent developments in adenosine A2A receptor ligands.
    Cristalli G; Müller CE; Volpini R
    Handb Exp Pharmacol; 2009; (193):59-98. PubMed ID: 19639279
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Myocardial perfusion imaging laboratory efficiency with the use of regadenoson compared to adenosine and dipyridamole.
    Friedman M; Spalding J; Kothari S; Wu Y; Gatt E; Boulanger L
    J Med Econ; 2013; 16(4):449-60. PubMed ID: 23363331
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Regadenoson: a new myocardial stress agent.
    Al Jaroudi W; Iskandrian AE
    J Am Coll Cardiol; 2009 Sep; 54(13):1123-30. PubMed ID: 19761931
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Caffeine attenuates the duration of coronary vasodilation and changes in hemodynamics induced by regadenoson (CVT-3146), a novel adenosine A2A receptor agonist.
    Zhao G; Messina E; Xu X; Ochoa M; Sun HL; Leung K; Shryock J; Belardinelli L; Hintze TH
    J Cardiovasc Pharmacol; 2007 Jun; 49(6):369-75. PubMed ID: 17577101
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Tachycardia caused by A2A adenosine receptor agonists is mediated by direct sympathoexcitation in awake rats.
    Dhalla AK; Wong MY; Wang WQ; Biaggioni I; Belardinelli L
    J Pharmacol Exp Ther; 2006 Feb; 316(2):695-702. PubMed ID: 16227469
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Initial clinical experience with regadenoson, a novel selective A2A agonist for pharmacologic stress single-photon emission computed tomography myocardial perfusion imaging.
    Hendel RC; Bateman TM; Cerqueira MD; Iskandrian AE; Leppo JA; Blackburn B; Mahmarian JJ
    J Am Coll Cardiol; 2005 Dec; 46(11):2069-75. PubMed ID: 16325044
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Selective adenosine A receptor agonist, ATL-146e, attenuates stress-induced gastric lesions in rats.
    Odashima M; Otaka M; Jin M; Komatsu K; Wada I; Matsuhashi T; Horikawa Y; Hatakeyama N; Oyake J; Ohba R; Linden J; Watanabe S
    J Gastroenterol Hepatol; 2005 Feb; 20(2):275-80. PubMed ID: 15683432
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Highlights on the development of A(2A) adenosine receptor agonists and antagonists.
    Cristalli G; Cacciari B; Dal Ben D; Lambertucci C; Moro S; Spalluto G; Volpini R
    ChemMedChem; 2007 Mar; 2(3):260-81. PubMed ID: 17177231
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Acute myocardial infarction during regadenoson myocardial perfusion imaging.
    Shah S; Parra D; Rosenstein RS
    Pharmacotherapy; 2013 Jun; 33(6):e90-5. PubMed ID: 23471769
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacologic stress testing: experience with dipyridamole, adenosine, and dobutamine.
    McGuinness ME; Talbert RL
    Am J Hosp Pharm; 1994 Feb; 51(3):328-46; quiz 404-5. PubMed ID: 8160685
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacological characterisation and inhibitory effects of (2R,3R,4S,5R)-2-(6-amino-2-{[(1S)-2-hydroxy-1-(phenylmethyl)ethyl]amino}-9H-purin-9-yl)-5-(2-ethyl-2H-tetrazol-5-yl)tetrahydro-3,4-furandiol, a novel ligand that demonstrates both adenosine A(2A) receptor agonist and adenosine A(3) receptor antagonist activity.
    Bevan N; Butchers PR; Cousins R; Coates J; Edgar EV; Morrison V; Sheehan MJ; Reeves J; Wilson DJ
    Eur J Pharmacol; 2007 Jun; 564(1-3):219-25. PubMed ID: 17382926
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Selective A2A adenosine receptor agonist as a coronary vasodilator in conscious dogs: potential for use in myocardial perfusion imaging.
    Trochu JN; Zhao G; Post H; Xu X; Belardinelli L; Belloni FL; Hintze TH
    J Cardiovasc Pharmacol; 2003 Jan; 41(1):132-9. PubMed ID: 12500031
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.